[{"id":"b02b627b-33be-4001-b108-f3ebe1518b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031558","created_at":"2023-09-11T16:10:34.173Z","updated_at":"2024-07-02T16:35:36.237Z","phase":"Phase 3","brief_title":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","source_id_and_acronym":"NCT06031558","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-5007"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 09/20/2024","primary_completion_date":" 09/20/2024","study_txt":" Completion: 06/20/2026","study_completion_date":" 06/20/2026","last_update_posted":"2023-09-21"},{"id":"985ab4d5-37c9-4b6d-a5be-3f7a1acef6ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05278364","created_at":"2022-03-14T13:54:01.472Z","updated_at":"2024-07-02T16:35:50.793Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","source_id_and_acronym":"NCT05278364","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" PD-L1 • RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET positive","tags":["PD-L1 • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-5007"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/10/2025","study_completion_date":" 02/10/2025","last_update_posted":"2023-04-12"}]